Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and...

Area of Science:

• Oncology
• Pharmacology

Background:

• Melanoma metastasis remains a significant cause of mortality, with over 70% of patients with distant metastasis dying within 5 years.
• Current treatments lack specific strategies to prevent early-stage melanoma from progressing to metastasis.
• Preventing metastasis is crucial for improving patient survival and reducing healthcare burdens.

Purpose of the Study:

• To identify potential therapeutic agents for preventing melanoma metastasis.
• To investigate the efficacy of statins in inhibiting melanoma progression.
• To explore the molecular mechanisms underlying statin's effect on melanoma.

Main Methods:

• In silico drug screening using the Connectivity Map identified statins as potential anti-metastatic agents.
• In vitro studies involved RNA sequencing of A375 melanoma cells treated with fluvastatin to analyze transcriptomic changes.
• A retrospective chart review of 475 melanoma patients was conducted to assess the association between statin use and metastasis at diagnosis.

Main Results:

• Statins demonstrated the ability to induce differential gene expression in pathways associated with metastasis.
• Genes affected by statins are implicated in commercially available melanoma prognostic tests.
• Patients on statins showed a significantly lower incidence of metastasis at melanoma diagnosis (24.7% vs. 37.6%, P=0.038).

Conclusions:

• Statins show promise as a preventative treatment to reduce melanoma metastasis.
• The findings suggest statins could be a valuable addition to early melanoma management strategies.
• Further prospective clinical trials are necessary to confirm these results and elucidate the precise mechanisms of action.